Krystal Biotech (KRYS) Free Cash Flow (2016 - 2026)

Krystal Biotech has disclosed Free Cash Flow across 11 years of filings, most recently posting $73.2 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $73.2 million, up 147.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $241.5 million (up 70.86% YoY), and the FY2025 annual result was $197.8 million, up 65.96% from the prior year.
• Free Cash Flow came in at $73.2 million for Q1 2026 at Krystal Biotech, down from $75.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $75.1 million in Q4 2025 to a low of -$62.3 million in Q2 2022.
• The 5-year median for Free Cash Flow is $1.9 million (2024), against an average of $10.4 million.
• Across the five-year window, Free Cash Flow tumbled 1557.42% in 2023 and soared 2325.83% in 2025, its largest moves.
• Krystal Biotech's Free Cash Flow stood at -$22.0 million in 2022, then surged by 78.45% to -$4.7 million in 2023, then jumped by 1200.02% to $52.0 million in 2024, then surged by 44.24% to $75.1 million in 2025, then decreased by 2.44% to $73.2 million in 2026.
• The last three Free Cash Flow figures came in at $73.2 million (Q1 2026), $75.1 million (Q4 2025), and $47.1 million (Q3 2025), per Business Quant data.